Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 404

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 404
---
asers, dated as of February 28, 2025.

Under the Gloperba-Elyxyb Royalty Security Agreement, each of our and Scilex Pharma’s due performance and payment under the
Gloperba-Elyxyb Royalty Purchase Agreement is secured by certain collateral, including a collection account and certain material contracts, intellectual property rights and regulatory approvals, in each case related to the Gloperba-Elyxyb Covered
Products.

Gloperba-Elyxyb Subordination Agreement

In connection with the Gloperba-Elyxyb Royalty Purchase Agreement and the Gloperba-Elyxyb Royalty Security Agreement, we entered into the
Gloperba-Elyxyb Subordination Agreement, by and among us, Scilex Pharma, the Gloperba-Elyxyb RPA Purchasers and the Note Agent. Pursuant to the Gloperba and Elyxyb Subordination Agreement, the parties agreed that all obligations, liabilities and
indebtedness under the Gloperba-Elyxyb Royalty Purchase Agreement are secured by the Gloperba-Elyxyb Royalty Collateral and the Note Agent’s lien on the Gloperba-Elyxyb Royalty Collateral is subordinated and becomes a second priority lien.

The foregoing summaries of the Gloperba-Elyxyb Royalty Purchase Agreement, the Gloperba-Elyxyb Royalty Security Agreement and the
Gloperba-Elyxyb Subordination Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, a copy of each of which is filed as an exhibit to our Current Report on Form 8-K filed on March 3, 2025.

252

Gloperba Rest of World License Agreement

On the Effective Date, we entered into the Gloperba License Agreement with Scilex Pharma and the Licensee with respect to (i) services,
compositions, products, dosages and formulations comprising Gloperba that have been or are later developed by or on behalf of us, including the product and any future product defined as a “Licensed Product” under the Romeg License
Agreement, as amended by that certain First Amendment to License and Commercialization Agreement, dated January 16, 2025, by and between Romeg and us, as may be further amended or restated from time to time, and (ii) any related, improved,
successor or replacement